[A21-105] Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36
Last updated 16.09.2021
Commission awarded on 10.08.2021 by the Federal Joint Committee (G-BA).
First-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
Unchanged after addendum:
- Patients for whom intensive therapy is appropriate: hint of considerable added benefit.
- Patients for whom intensive therapy is not appropriate: added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.